Bayer
As of the edition of 20 October 2026, Bayer runs 222 drugs, 123 of them marketed; it is on route A at 27 targets and on route B at 49 targets.
Sources: ClinicalTrials.gov, FDA Orange Book and Purple Book, other approval registers, company records.
Family history
The records place 11 company names in this family.
- Miles Laboratories Inc: acquired in 1978; successor Bayer A.G.
- AskBio Inc: acquired in 2020; successor Bayer A.G.
Drugs by status
| Status | Count |
|---|---|
| Marketed | 123 |
| Active | 18 |
| Went quiet | 33 |
| Stopped | 28 |
| Withdrawn from market | 1 |
| Status not established | 19 |
| Total | 222 |
Marketed drugs and when their US protection ends
| Drug | US protection | Route B rows |
|---|---|---|
| Rituximab | Ends 2028 (orphan exclusivity) | 1 |
| Fludarabine | none listed | 2 |
| Acetaminophen | none listed | 17 |
| Aspirin | none listed | 8 |
| Sorafenib | Ends 2027 (patent) | 1 |
| Cholecalciferol | none listed | 2 |
| Ibuprofen | none listed | 11 |
| Fludarabine phosphate | none listed | 1 |
| Rivaroxaban | none listed | 2 |
| Aflibercept | Ends 2030 (orphan exclusivity) | 4 |
| Sodium chloride | none listed | 0 |
| Caffeine | none listed | 12 |
| Moxifloxacin | none listed | 0 |
| Hydrocortisone | none listed | 5 |
| Regorafenib | Ends 2032 (patent) | 8 |
| Hydrochlorothiazide | none listed | 4 |
| Estradiol | Ends 2032 (patent) | 6 |
| Telmisartan | none listed | 2 |
| Ethinyl estradiol | none listed | 5 |
| Folic acid | none listed | 0 |
| Ascorbic acid | none listed | 0 |
| Fluconazole | none listed | 0 |
| Ciprofloxacin | none listed | 0 |
| Levonorgestrel | none listed | 4 |
| Naproxen | none listed | 2 |
A route B row is one company at one target. 98 more marketed drugs are not listed here.
Where it needs a new molecule
Route A at 27 targets, route B at 49 targets.
All 76 rows on route A or B
In the product76 company-target rows on route A or B; 73 are not shown here, and no score is.
See all 76 targets where Bayer needs a new molecule, with the facts behind eachRequest access. Nothing is shown until you do.
Where its trials are
- Cancer: 256 trials led
- Urinary and reproductive: 162 trials led
- Pregnancy and women's health: 110 trials led